Role of Class II MHC Antigens in Neurologic Diseases
Role of Class II MHC Antigens in Neurologic Diseases
批准号:
6529158
负责人:
Jenny P Ting
金额:
$32.61万
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-08-15 至 2006-07-31
中文摘要
描述(申请人提供):MHC II类分子以
中枢神经系统(CNS)在一些神经系统疾病和
脱髓鞘疾病。在大多数此类疾病中,T细胞通常是
在受影响的中枢神经系统中不存在。解决第二类MHC在中枢神经系统中的重要性
我们描述了两种脱髓鞘模型,它们展示了
II MHC高表达于小胶质细胞。这些疾病的特征
模型表明,第二类MHC的缺失导致外显性MHC的缓解
症状,神经病理/脱髓鞘减少,小胶质细胞减少
激活/增殖,减少炎性细胞因子的产生。多数
有趣的是,第二类MHC的作用不受T细胞缺失的影响
在RAGb小鼠中,但依赖于完整的II类MHC胞浆尾巴。这
导致我们提出II类可能在Signal中起体内作用
不同于其在抗原中的常规生物学作用的转导
展示。目标是:
1.分析转基因小鼠品系H-2M对铜草酮的反应
治疗。如果常规的抗原处理不重要,那么
H-2m的缺失不应影响铜试剂诱导的脱髓鞘。
2.分析II类MHC和T细胞对髓鞘再生过程的影响。近期
我们实验室的研究表明,炎性细胞因子是
对于最佳的髓鞘再生来说是必要的。MHC II类物质的存在导致
细胞因子表达增强,因此及时确定其作用
MHC在重新髓鞘形成过程中的作用,以及淋巴细胞是否参与这一过程。
3.确定新的II类MHC介导的信号转导介质。我们会
确定最近发现的II类信号的介体、细胞
小胶质细胞/巨噬细胞的激活和增殖受到影响。
4.确定在第二类MHC参与时被激活的基因。在一个
通过Affy Metrix筛选小胶质细胞-巨噬细胞系,并评估其状态
这些基因在铜试剂模型中。
英文摘要
DESCRIPTION (provided by applicant): MHC class II molecules are expressed in
the central nervous system (CNS) during a number of neurologic disorders and
demyelinating disease. In a majority of these diseases, T cells are generally
absent in the affected CNS. To address the importance of class II MHC in CNS
disorders, we have characterized two models of demyelination that exhibit class
II MHC hyper-expression on microglial cells. Characterizations of these disease
models show that the deletion of class II MHC caused the alleviation of overt
symptoms, reduced neuropathology/demyelination, reduced microglial
activation/proliferation and reduced production of inflammatory cytokines. Most
intriguingly, the role of class II MHC is unaffected by the absence of T cells
in RAGb mice, but dependent on an intact class II MHC cytoplasmic tail. This
caused us to propose that class II may serve an in vivo role in signal
transduction, distinct from its conventional biologic role in antigen
presenting. The Aims are:
1.Analyze a transgenic mouse strain, H-2M for its response to cuprizone
treatment. If conventional antigen processing is not important, then the
deletion of H-2M should not affect cuprizone-induced demyelination.
2.Analyze how class II MHC and T cells affect the remyelination process. Recent
studies in our laboratory have demonstrated that inflammatory cytokines are
necessary for optimal remyelination. The presence of MHC class II causes
enhanced cytokine expression, therefore it is timely to determine the role of
MHC during remyelination, and if lymphocytes are involved in this process.
3. Determine novel mediators of class II MHC-mediated signaling. We will
determine if recently discovered mediators of class II signaling, cell
activation and proliferation are affected in microglia/macrophages.
4. Identify genes that are activated upon class II MHC engagement. in a
microglial-macrophage line by Affy metrix screening, and assess the status of
these genes in the cuprizone model.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Intracellular Innate Immune Receptors in Cancer Suppression and Immunotherapy
-
批准号:10654660
-
项目类别:
-
资助金额:$90.61万
-
财政年份:2019
-
负责人:Jenny P Ting
-
依托单位:
Intracellular Innate Immune Receptors in Cancer Suppression and Immunotherapy
-
批准号:10451800
-
项目类别:
-
资助金额:$90.55万
-
财政年份:2019
-
负责人:Jenny P Ting
-
依托单位:
Intracellular Innate Immune Receptors in Cancer Suppression and Immunotherapy
-
批准号:10217045
-
项目类别:
-
资助金额:$92.43万
-
财政年份:2019
-
负责人:Jenny P Ting
-
依托单位:
Intracellular Innate Immune Receptors in Cancer Suppression and Immunotherapy
-
批准号:10019472
-
项目类别:
-
资助金额:$92.59万
-
财政年份:2019
-
负责人:Jenny P Ting
-
依托单位:
Novel Nanoparticle Platform for the delivery of Vaccines and Adjuvants
-
批准号:8642227
-
项目类别:
-
资助金额:$360.31万
-
财政年份:2014
-
负责人:Jenny P Ting
-
依托单位:
Novel Nanoparticle Platform for the delivery of Vaccines and Adjuvants
-
批准号:9229872
-
项目类别:
-
资助金额:$13.23万
-
财政年份:2014
-
负责人:Jenny P Ting
-
依托单位:
Engineering Monodisperse Particulate Vaccines to Tailor Immunological Responses
-
批准号:9337971
-
项目类别:
-
资助金额:$13.23万
-
财政年份:2014
-
负责人:Jenny P Ting
-
依托单位:
Discovery of New Innate Immune Pathways in Viral Recognition
-
批准号:8653231
-
项目类别:
-
资助金额:$316.37万
-
财政年份:2014
-
负责人:Jenny P Ting
-
依托单位:
Novel Nanoparticle Platform for the delivery of Vaccines and Adjuvants
-
批准号:9307701
-
项目类别:
-
资助金额:$466.6万
-
财政年份:2014
-
负责人:Jenny P Ting
-
依托单位:
Novel Nucleic Acid Sensing NLRs and Innate Immunity to Viruses
-
批准号:9233910
-
项目类别:
-
资助金额:$41.68万
-
财政年份:2014
-
负责人:Jenny P Ting
-
依托单位:
NOD-like Receptors in Intestinal Inflammation
-
批准号:10447741
-
项目类别:
-
资助金额:$35.34万
-
财政年份:2013
-
负责人:Jenny P Ting
-
依托单位:
NOD-like Receptors in Intestinal Inflammation
-
批准号:10216239
-
项目类别:
-
资助金额:$35.25万
-
财政年份:2013
-
负责人:Jenny P Ting
-
依托单位:
NOD-like Receptors in Intestinal Inflammation
-
批准号:10642795
-
项目类别:
-
资助金额:$35.34万
-
财政年份:2013
-
负责人:Jenny P Ting
-
依托单位:
Novel roles of the NLR protein in host response against WNV and DENV
-
批准号:8375882
-
项目类别:
-
资助金额:$25.69万
-
财政年份:2012
-
负责人:Jenny P Ting
-
依托单位:
Novel roles of the NLR protein in host response against WNV and DENV
-
批准号:8234189
-
项目类别:
-
资助金额:$24.52万
-
财政年份:2011
-
负责人:Jenny P Ting
-
依托单位:
Colitis, colon cancer and the NLR family
-
批准号:8445358
-
项目类别:
-
资助金额:$31.07万
-
财政年份:2011
-
负责人:Jenny P Ting
-
依托单位:
Colitis, colon cancer and the NLR family
-
批准号:8840704
-
项目类别:
-
资助金额:$9.09万
-
财政年份:2011
-
负责人:Jenny P Ting
-
依托单位:
Colitis, colon cancer and the NLR family
-
批准号:8043373
-
项目类别:
-
资助金额:$33.22万
-
财政年份:2011
-
负责人:Jenny P Ting
-
依托单位:
Colitis, colon cancer and the NLR family
-
批准号:8260497
-
项目类别:
-
资助金额:$33.14万
-
财政年份:2011
-
负责人:Jenny P Ting
-
依托单位:
Immunology Program
-
批准号:8340200
-
项目类别:
-
资助金额:$18.8万
-
财政年份:2011
-
负责人:Jenny P Ting
-
依托单位:
海外基金